Abstract
Glioblastoma (GBM) accounts for approximately half of all malignant brain tumors, and it remains lethal with a five-year survival of less than 10%. Despite the immense advancements in the field, it has managed to evade even the most promising therapeutics: immunotherapies. The main reason is the highly spatiotemporally heterogeneous and immunosuppressive GBM tumor microenvironment (TME). Accounting for this complex interplay of TME-driven immunosuppression is key to developing effective therapeutics. This review will explore the immunomodulatory role of the extracellular matrix (ECM) by establishing its contribution to the TME as a key mediator of immune responses in GBM. This relationship will help us elucidate therapeutic targets that can be leveraged to develop and deliver more effective immunotherapies.
| Original language | English (US) |
|---|---|
| Article number | 1336476 |
| Journal | Frontiers in immunology |
| Volume | 15 |
| DOIs | |
| State | Published - 2024 |
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CL-C is supported by the National Cancer Institute (NCI, NIH) grants R37CA258426 and P50CA221747, the Cancer Research Institute CLIP grant CRI4896 and the Malnati Brain Tumor Institute. JM is supported by the National Institute of Neurological Disorders and Stroke (NINDS, NIH) grant 1R01NS115955 and the National Cancer Institute (NCI, NIH) grants 1R01CA279686 and P50CA221747. Acknowledgments
Keywords
- cancer-associated fibroblasts
- collagen
- decorin
- extracellular matrix
- fibronectin
- glioblastoma
- immunotherapy
- tumor microenvironment
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
